{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:56:56Z","timestamp":1793325416671,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-05417-z","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T09:23:00Z","timestamp":1735550580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Paolo","family":"Zaurito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Longoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Quarta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tremolada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"issue":"1","key":"5417_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier S, Sylvester RJ, Collette L et al (2016) EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance Bacillus Calmette-Gu\u00e9rin. Eur Urol 69(1):60\u201369. https:\/\/doi.org\/10.1016\/j.eururo.2015.06.045","journal-title":"Eur Urol"},{"issue":"3","key":"5417_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013477. https:\/\/doi.org\/10.1016\/j.eururo.2005.12.031","journal-title":"Eur Urol"},{"issue":"1","key":"5417_CR3","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O et al (2022) European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"issue":"4","key":"5417_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V et al (2021) European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel [published correction appears in Eur Urol. 2023 May;83(5):e140-e141. 10.1016\/j.eururo.2023.02.007]. Eur Urol 79(4):480\u2013488. https:\/\/doi.org\/10.1016\/j.eururo.2020.12.033","journal-title":"Eur Urol"},{"issue":"2","key":"5417_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","volume":"192","author":"AM Kamat","year":"2014","unstructured":"Kamat AM, Witjes JA, Brausi M et al (2014) Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. J Urol 192(2):305\u2013315. https:\/\/doi.org\/10.1016\/j.juro.2014.02.2573","journal-title":"J Urol"},{"issue":"5","key":"5417_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","volume":"5","author":"WS Tan","year":"2022","unstructured":"Tan WS, Steinberg G, Witjes JA et al (2022) Intermediate-risk non-muscle-invasive bladder cancer: updated consensus definition and management recommendations from the International bladder cancer group. Eur Urol Oncol 5(5):505\u2013516. https:\/\/doi.org\/10.1016\/j.euo.2022.05.005","journal-title":"Eur Urol Oncol"},{"key":"5417_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.06.004","author":"F Soria","year":"2024","unstructured":"Soria F, Rosazza M, Livoti S et al (2024) Clinical validation of the intermediate-risk non-muscle-invasive bladder cancer scoring system and substratification model proposed by the International bladder cancer group: a multicenter young academic urologists urothelial working group collaboration. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.06.004","journal-title":"Eur Urol Oncol"},{"issue":"2 Pt 1","key":"5417_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","volume":"170","author":"MS Soloway","year":"2003","unstructured":"Soloway MS, Bruck DS, Kim SS (2003) Expectant management of small, recurrent, noninvasive papillary bladder tumors. J Urol 170(2 Pt 1):438\u2013441. https:\/\/doi.org\/10.1097\/01.ju.0000076621.71247.6c","journal-title":"J Urol"},{"issue":"4","key":"5417_CR9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.euf.2023.03.025","volume":"9","author":"R Contieri","year":"2023","unstructured":"Contieri R, Lazzeri M, Hurle R (2023) When and how to perform active surveillance for low-risk non-muscle-invasive bladder cancer. Eur Urol Focus 9(4):564\u2013566. https:\/\/doi.org\/10.1016\/j.euf.2023.03.025","journal-title":"Eur Urol Focus"},{"issue":"5","key":"5417_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/JU.0000000000003639","volume":"210","author":"WS Tan","year":"2023","unstructured":"Tan WS, Contieri R, Buffi NM et al (2023) International bladder cancer group intermediate-risk nonmuscle-invasive bladder cancer scoring system predicts outcomes of patients on active surveillance. J Urol 210(5):763\u2013770. https:\/\/doi.org\/10.1097\/JU.0000000000003639","journal-title":"J Urol"},{"issue":"1","key":"5417_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.21037\/tau.2018.10.20","volume":"8","author":"G Marcq","year":"2019","unstructured":"Marcq G, H\u00e9non F, Ouzaid I, Fantoni JC, Hermieu JF, Xylinas E (2019) Active surveillance for non-muscle invasive bladder cancer. Transl Androl Urol 8(1):54\u201360. https:\/\/doi.org\/10.21037\/tau.2018.10.20","journal-title":"Transl Androl Urol"},{"issue":"4","key":"5417_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/21681805.2020.1782978","volume":"54","author":"MS Erikson","year":"2020","unstructured":"Erikson MS, Petersen AC, Andersen KK, Jacobsen FK, Mogensen K, Hermann GG (2020) Do repeated transurethral procedures under general anesthesia influence mortality in patients with non-invasive urothelial bladder cancer? A Danish national cohort study. Scand J Urol 54(4):281\u2013289. https:\/\/doi.org\/10.1080\/21681805.2020.1782978","journal-title":"Scand J Urol"},{"issue":"8","key":"5417_CR13","doi-asserted-by":"publisher","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","volume":"20","author":"TW Flaig","year":"2022","unstructured":"Flaig TW, Spiess PE, Abern M et al (2022) NCCN guidelines\u00ae insights: bladder cancer, version 2.2022. J Natl Compr Canc Netw 20(8):866\u2013878. https:\/\/doi.org\/10.6004\/jnccn.2022.0041","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"5417_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.eururo.2011.05.033","volume":"60","author":"J Fernandez-Gomez","year":"2011","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2011) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: external validation of the EORTC risk tables. Eur Urol 60(3):423\u2013430. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.033","journal-title":"Eur Urol"},{"issue":"5","key":"5417_CR15","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.euf.2021.06.007","volume":"8","author":"S Ourfali","year":"2022","unstructured":"Ourfali S, Matillon X, Ricci E et al (2022) Prognostic implications of treatment delays for patients with non-muscle-invasive bladder cancer. Eur Urol Focus 8(5):1226\u20131237. https:\/\/doi.org\/10.1016\/j.euf.2021.06.007","journal-title":"Eur Urol Focus"},{"issue":"6","key":"5417_CR16","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1097\/JU.0000000000001633","volume":"205","author":"JT Matulay","year":"2021","unstructured":"Matulay JT, Li R, Hensley PJ et al (2021) Contemporary outcomes of patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin: implications for clinical trial design. J Urol 205(6):1612\u20131621. https:\/\/doi.org\/10.1097\/JU.0000000000001633","journal-title":"J Urol"},{"issue":"5","key":"5417_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/UPJ.0000000000000631","volume":"11","author":"H Herr","year":"2024","unstructured":"Herr H (2024) De-escalation of therapy for low-grade papillary bladder tumors with preserved long-term oncologic outcomes. Urol Pract 11(5):777\u2013780. https:\/\/doi.org\/10.1097\/UPJ.0000000000000631","journal-title":"Urol Pract"},{"key":"5417_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.06.026","author":"P Scilipoti","year":"2024","unstructured":"Scilipoti P, Longoni M, de Angelis M et al (2024) Mitomycin C vs. Bacillus Calmette-Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients. A comparative analysis from a single center. Urol Oncol. https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.026","journal-title":"Urol Oncol"},{"key":"5417_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.06.005","author":"P Scilipoti","year":"2024","unstructured":"Scilipoti P, \u015alusarczyk A, de Angelis M et al (2024) The role of mitomycin c in intermediate-risk non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2024.06.005","journal-title":"Eur Urol Oncol."},{"issue":"4","key":"5417_CR20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","volume":"52","author":"MG Friedrich","year":"2007","unstructured":"Friedrich MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H (2007) Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52(4):1123\u20131129. https:\/\/doi.org\/10.1016\/j.eururo.2007.02.063","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05417-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05417-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05417-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:03:32Z","timestamp":1767996212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05417-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5417"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05417-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4902791\/v1","asserted-by":"object"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"12 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"52"}}